Kinase-targeted cancer therapies: progress, challenges and future directions.

about

Kinase-targeted cancer therapies: progress, challenges and future directions.

Item

http://www.wikidata.org/entity/Q49887882

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Kinase-targeted cancer therapies: progress, challenges and future directions.

@en

Kinase-targeted cancer therapies: progress, challenges and future directions.

@nl

type

Item

label

Kinase-targeted cancer therapies: progress, challenges and future directions.

@en

Kinase-targeted cancer therapies: progress, challenges and future directions.

@nl

prefLabel

Kinase-targeted cancer therapies: progress, challenges and future directions.

@en

Kinase-targeted cancer therapies: progress, challenges and future directions.

@nl

P1476

Kinase-targeted cancer therapies: progress, challenges and future directions.

@en

P2093

Amitabh Jha

http://www.w3.org/2001/XMLSchema#string

Basil P Hubbard

http://www.w3.org/2001/XMLSchema#string

Eileen M McGowan

http://www.w3.org/2001/XMLSchema#string

H P Vasantha Rupasinghe

http://www.w3.org/2001/XMLSchema#string

Indu Parmar

http://www.w3.org/2001/XMLSchema#string

Khushwant S Bhullar

http://www.w3.org/2001/XMLSchema#string

Naiara Orrego Lagarón

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways

Cellular signaling by fibroblast growth factor receptors

Survival of cancer cells is maintained by EGFR independent of its kinase activity

The protein kinase complement of the human genome

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

A census of human cancer genes

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Luteolin, a flavonoid with potential for cancer prevention and therapy

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

P2888

s12943-018-0804-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S12943-018-0804-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101066805

http://www.w3.org/2001/XMLSchema#string

P698

29455673

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

mechanism of action

Anzim

P932

5817855

http://www.w3.org/2001/XMLSchema#string